Commencement of two pivotal BIT225 clinical trials
Filed with ASX · · 5 pages · English
Earlier from Biotron
- Quarterly Cash Flow Report
- Full Year Statutory Accounts and Preliminary Final Report
- $1.4M R&D Tax Rebate
- Appendix 4C - quarterly
- Quarterly Cashflow Report
Later from Biotron
- Biotron drug effective against COVID-19 in animals
- Quarterly Appendix 4C Cash Flow Report
- BIT225 Effectiveness Against COVID-19 in Animals
- $1.56M R&D Rebate Received
- Quarterly Activities Report
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron